selected publications
-
Characterization of on-target adverse events caused by TRK inhibitor therapy.
Annals of oncology : official journal of the European Society for Medical Oncology.
2020
Academic Article
GET IT
Times cited: 47 -
Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2018
Academic Article
GET IT
Times cited: 91 -
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
Annals of oncology : official journal of the European Society for Medical Oncology.
2018
Academic Article
GET IT
Times cited: 247 -
Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2018
Academic Article
GET IT
Times cited: 259 -
Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors.
Therapeutics and clinical risk management.
2018
Review
GET IT
Times cited: 90 -
Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
2018
Academic Article
GET IT
Times cited: 156 -
Tumor-Agnostic Drug Development.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
2018
Academic Article
GET IT
Times cited: 35 -
Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA.
Journal of oncology.
2017
Review
GET IT
Times cited: 21